Equities research analysts forecast that Iqvia Holdings Inc (NYSE:IQV) will post sales of $2.58 billion for the current quarter, Zacks Investment Research reports. Eleven analysts have made estimates for Iqvia’s earnings. The highest sales estimate is $2.59 billion and the lowest is $2.57 billion. Iqvia reported sales of $2.02 billion in the same quarter last year, which indicates a positive year over year growth rate of 27.7%. The business is expected to report its next quarterly earnings report on Thursday, October 25th.

According to Zacks, analysts expect that Iqvia will report full-year sales of $10.35 billion for the current financial year, with estimates ranging from $10.21 billion to $10.44 billion. For the next financial year, analysts anticipate that the business will post sales of $10.92 billion, with estimates ranging from $10.78 billion to $11.01 billion. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for Iqvia.

Iqvia (NYSE:IQV) last released its earnings results on Tuesday, July 24th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.15. The company had revenue of $2.57 billion for the quarter, compared to analyst estimates of $2.50 billion. Iqvia had a return on equity of 13.51% and a net margin of 12.68%. Iqvia’s revenue for the quarter was up 9.0% on a year-over-year basis.

Several analysts recently weighed in on the company. Royal Bank of Canada reaffirmed a “$110.25” rating and issued a $128.00 price objective on shares of Iqvia in a research note on Thursday, July 19th. Argus set a $136.00 price objective on Iqvia and gave the company a “buy” rating in a research note on Thursday, August 23rd. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $97.00 price objective on shares of Iqvia in a research note on Wednesday, July 25th. Barclays reaffirmed an “overweight” rating and issued a $130.00 price objective (up from $120.00) on shares of Iqvia in a research note on Wednesday, July 25th. Finally, Bank of America raised Iqvia from a “neutral” rating to a “buy” rating and set a $135.00 price objective on the stock in a research note on Wednesday, July 25th. Five research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $126.95.

In other news, insider Ari Bousbib sold 368,640 shares of the firm’s stock in a transaction dated Thursday, July 26th. The stock was sold at an average price of $122.09, for a total transaction of $45,007,257.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John G. Danhakl sold 370,470 shares of the firm’s stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of $124.83, for a total value of $46,245,770.10. The disclosure for this sale can be found here. Insiders have sold 978,777 shares of company stock worth $121,566,089 over the last three months. Insiders own 6.00% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Steward Partners Investment Advisory LLC raised its position in shares of Iqvia by 19.4% during the second quarter. Steward Partners Investment Advisory LLC now owns 2,933 shares of the medical research company’s stock worth $293,000 after acquiring an additional 476 shares during the last quarter. Louisiana State Employees Retirement System raised its position in shares of Iqvia by 6.7% during the second quarter. Louisiana State Employees Retirement System now owns 9,500 shares of the medical research company’s stock worth $948,000 after acquiring an additional 600 shares during the last quarter. AMP Capital Investors Ltd raised its position in shares of Iqvia by 1.3% during the second quarter. AMP Capital Investors Ltd now owns 48,272 shares of the medical research company’s stock worth $4,818,000 after acquiring an additional 600 shares during the last quarter. Private Capital Group LLC raised its position in shares of Iqvia by 177.0% during the first quarter. Private Capital Group LLC now owns 1,061 shares of the medical research company’s stock worth $104,000 after acquiring an additional 678 shares during the last quarter. Finally, Howard Capital Management raised its position in shares of Iqvia by 0.6% during the second quarter. Howard Capital Management now owns 125,625 shares of the medical research company’s stock worth $12,540,000 after acquiring an additional 710 shares during the last quarter. Institutional investors own 91.91% of the company’s stock.

Shares of IQV traded up $2.21 during trading hours on Friday, hitting $124.79. 815,081 shares of the company were exchanged, compared to its average volume of 1,246,798. The firm has a market cap of $26.28 billion, a P/E ratio of 28.62, a price-to-earnings-growth ratio of 1.86 and a beta of 0.70. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.13 and a current ratio of 1.13. Iqvia has a fifty-two week low of $91.57 and a fifty-two week high of $132.24.

About Iqvia

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Further Reading: Marijuana Stocks Investing Considerations

Get a free copy of the Zacks research report on Iqvia (IQV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.